 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2712-------------------------------------------------- |
|
Ocrelizumab and liver injury research information (PubMed) |
|
By: agate Date: November 4, 2019, 6:43 pm |
|
--------------------------------------------------------- |
|
The Overview section of the report on Ocrevus that is part of a |
|
larger report entitled LiverTox: Clinical and Research |
|
Information on Drug-Induced Liver Injury, issued by the National |
|
Institute of Diabetes and Digestive and Kidney Diseases. This |
|
section was last updated in July 2018.[font=arial] |
|
https://www.ncbi.nlm.nih.gov/books/NBK548145/#Ocrelizumab.OVERVIEW[/font] |
|
The "likelihood score" for Ocrevus is E*, which is defined as: |
|
[quote][font=comic sans ms]Category E*.[/font] The drug is |
|
suspected to be capable of causing liver injury or idiosyncratic |
|
acute liver injury but there have been no convincing cases in |
|
the medical literature. In some situations cases of acute liver |
|
injury have been reported to regulatory agencies or mentioned in |
|
large clinical studies of the drug, but the specifics and |
|
details supportive of causality assessment are not available. |
|
The agent is unproven, but suspected to cause liver |
|
injury.[/quote] |
|
***************************************************** |
